Sunrest Lifescience (NSE:SUNREST) Research & Development: ₹0.0 Mil (TTM As of Mar. 2026)


NSE:SUNREST Sunrest Lifescience Ltd NSE:SUNREST
41 GF Score
Price ₹35.05
! 5 Warning Signs
View Full Analysis

What is Sunrest Lifescience Research & Development?

Sunrest Lifescience NSE:SUNREST 41 Research & Development is ₹0.0 Mil as of Mar. 2026. GuruFocus rates NSE:SUNREST with a GF Score™ of 41/100. The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Sunrest Lifescience's Research & Development for the six months ended in Mar. 2026 was ₹0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0.0 Mil.

Sunrest Lifescience  (NSE:SUNREST) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Sunrest Lifescience Research & Development Related Terms

Sunrest Lifescience Research & Development Historical Data

* Premium members only.

The historical data trend for Sunrest Lifescience's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sunrest Lifescience Research & Development Chart

Sunrest Lifescience Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Sunrest Lifescience Semi-Annual Data
Mar20 Mar21 Mar22 Mar23 Sep23 Mar24 Sep24 Mar25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:SUNREST
41GF Score
Sunrest Lifescience Ltd NSE:SUNREST
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sunrest Lifescience Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ₹0.0 Mil mean?
Sunrest Lifescience (NSE:SUNREST) has a Research & Development of ₹0.0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Sunrest Lifescience and its competitors.
Is Sunrest Lifescience's Research & Development too high?
Sunrest Lifescience's current Research & Development is ₹0.0 Mil. Overall, Sunrest Lifescience has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Sunrest Lifescience's Research & Development compare to competitors?
Sunrest Lifescience's Research & Development of ₹0.0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Sunrest Lifescience and its competitors. Sunrest Lifescience's current Research & Development is ₹0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunrest Lifescience stock overvalued right now?
Sunrest Lifescience (NSE:SUNREST) has a current Research & Development of ₹0.0 Mil. The current Research & Development is ₹0.0 Mil. Sunrest Lifescience's overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Sunrest Lifescience (NSE:SUNREST), the current Research & Development is ₹0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sunrest Lifescience Business Description

Address YMCA Club, Near SG Highway, D-608 West Gate, Near Brooklin Tower, Makarba, Jivraj Park, Ahmedabad, GJ, IND, 380051
Sunrest Lifescience Ltd is engaged in the trading business of pharmaceutical products, including capsules, tablets, syrups, ointments, gels, mouthwash, and toothpaste on a wholesale and retail basis. Its product portfolio covers categories such as anti-bacterial, anti-diarrheal, anti-fungal, anti-malarial, anti-diabetic, dental care, anti-inflammatory, nutraceuticals, and more. The company works with a network of suppliers and super suppliers, distributing products to chemists, hospitals, and dispensaries across multiple Indian states. Sunrest relies on both in-house manufacturing through its group company Trilend Pharmaceuticals and third-party manufacturers, emphasizing quality control and regulatory compliance.
41GF Score

Get the complete analysis for NSE:SUNREST

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹35.05
Price